Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jacquelynn Dimuccio

Physician Assistant Cranston, RI Physician Assistant

NPI 1275155574 CMS profile 10981229

1150 Reservoir Ave Ste 203, Cranston, RI 02920

Open in the dashboard

General payments

$5,096

257 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacquelynn Dimuccio of Cranston, RI is reported in the CMS Open Payments database as having received $5,096 across 257 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,616 82
2024 General $2,003 103
2023 General $231 10
2022 General $431 20
2021 General $816 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacquelynn Dimuccio
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jacquelynn Dimuccio were reported at $1,616. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jacquelynn Dimuccio Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $816 $132 $37–$438 $132
2022 $431 $155 $48–$522 $149
2023 $231 $167 $52–$557 $160
2024 $2,003 $178 $55–$600 $164
2025 $1,616 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,629 78 payments
  2. Teva Pharmaceuticals USA, Inc. $632 31 payments
  3. Otsuka America Pharmaceutical, Inc. $435 30 payments
  4. Vanda Pharmaceuticals Inc. $379 18 payments
  5. Lundbeck LLC $371 24 payments
  6. Alkermes, Inc. $344 16 payments
  7. ITI, Inc. $204 10 payments
  8. Neurocrine Biosciences, Inc. $183 7 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $136 6 payments
  10. Supernus Pharmaceuticals, Inc. $135 7 payments
  11. Other $648 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,921 255 payments
  2. Education $175 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $1,295 63 payments
  2. FANAPT $379 18 payments
  3. REXULTI Psychiatry $350 23 payments
  4. LYBALVI $344 16 payments
  5. REXULTI Psychiatry $337 25 payments
  6. VRAYLAR Neuroscience $306 14 payments
  7. Austedo XR $284 18 payments
  8. ARISTADA Cns $267 13 payments
  9. ARISTADA Cns $267 13 payments
  10. ARISTADA Cns $267 13 payments
  11. Other $2,155 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

579

Median for Physician Assistant: 241

Drug cost

$8,299

Median for Physician Assistant: $4,110

Branded share of claims

15%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 13 $2,088
Aripiprazole Generic 19 $847
Lamotrigine Generic 91 $772
Fluoxetine Hcl Generic 29 $588
Buspirone Hcl Generic 48 $568
Bupropion Xl Bupropion Hcl Brand 18 $534
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 17 $392
Divalproex Sodium Er Divalproex Sodium Brand 13 $277
Risperidone Generic 19 $256
Oxcarbazepine Generic 12 $247

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$11,376

Medicare's payments for the services billed

Medicare patients

17

Average age 63

Services billed

210

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 71%
Ischemic heart disease 0%
COPD 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $172
  • Otsuka America Pharmaceutical, Inc. $158
$331 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $198
$198 — —
ARISTADA
  • Alkermes, Inc. $191
$191 — —
VRAYLAR
  • AbbVie, Inc. $187
$187 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $164
$164 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record